To include your compound in the COVID-19 Resource Center, submit it here.

High five for Arsanis

Arsanis finds neutralizing antibody against five Staphylococcus aureus toxins

Researchers at Arsanis Inc. and Adimab LLC have identified an antibody that simultaneously neutralizes five Staphylococcus aureus toxins - defying the odds of hitting such diverse structures by fishing out an exposed conserved patch. While Arsanis is moving this compound towards the clinic, Adimab is doubling down on the screening strategy and hopes it will yield cross-neutralizing antibodies for other indications as well.

Eszter Nagy, president and CEO of Arsanis, told BioCentury hitting multiple toxins together could extend protection against S. aureus to antibiotic-resistant strains, while preventing tissue damage caused by all the strains. The antibodies in clinical testing neutralize only one toxin, she said, but blocking the toxins together should produce much greater efficacy because the toxins act on different subsets of cells.

The five toxins include aHL, a hemolysin that is toxic to lung and epithelial cells, and four leukocidins that are cytotoxic to red and white blood cells.

"What is exceptional about this antibody is that it also protects the immune cells which are lysed by the bi-component leukocidins," said Nagy. "We compared the potency of the cross-reactive antibody versus the aHL-specific antibody and we see exceptional potency and a great difference because

Read the full 1969 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE